STOCK TITAN

Gilead Sciences (CYPH) discloses 0% beneficial stake in Cypherpunk Technologies

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Cypherpunk Technologies Inc. (CYPH) is the subject of an amended Schedule 13G filing by Gilead Sciences, Inc. covering its holdings of Cypherpunk common stock, par value $0.001 per share, CUSIP 52187K200.

Gilead now reports beneficial ownership of 0 shares of Cypherpunk common stock, representing 0% of the class, with no sole or shared voting or dispositive power. The filing states that Gilead's ownership is now "5 percent or less" of the class.

Gilead certifies that any securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cypherpunk, nor in connection with any transaction intended to have that effect.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



GILEAD SCIENCES, INC.
Signature:/s/ Andrew D. Dickinson
Name/Title:Andrew D. Dickinson, Executive Vice President and Chief Financial Officer
Date:02/12/2026

FAQ

What does Gilead Sciences report about its ownership of Cypherpunk Technologies (CYPH)?

Gilead Sciences reports beneficial ownership of 0 shares of Cypherpunk Technologies common stock, representing 0% of the class. The Schedule 13G/A confirms Gilead has no sole or shared voting or dispositive power over CYPH shares.

Why did Gilead Sciences file an amended Schedule 13G/A for CYPH?

Gilead filed the amended Schedule 13G/A to report that it now beneficially owns 0 shares, or 0% of Cypherpunk’s common stock. The filing reflects that its holdings have fallen to 5 percent or less of the class.

What class of securities does the Gilead filing cover for Cypherpunk Technologies (CYPH)?

The filing covers Cypherpunk Technologies’ common stock, with a par value of $0.001 per share and CUSIP number 52187K200. All reported ownership and percentage figures in the Schedule 13G/A relate specifically to this class.

Does Gilead Sciences seek to influence control of Cypherpunk Technologies (CYPH)?

Gilead certifies that any Cypherpunk securities referenced were acquired and are held in the ordinary course of business. It states they were not acquired or held to change or influence control of Cypherpunk or in any transaction designed for that purpose.

What voting and dispositive powers over CYPH shares does Gilead report?

Gilead reports 0 shares with sole voting power, 0 with shared voting power, 0 with sole dispositive power, and 0 with shared dispositive power. This indicates no reported ability to vote, sell, or direct the disposition of any CYPH shares.

Who signed the Gilead Schedule 13G/A related to Cypherpunk Technologies?

The Schedule 13G/A was signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer of Gilead Sciences, Inc. The signature certifies that the information in the ownership statement is true, complete, and correct.
Leap Therapeutic

NASDAQ:LPTX

LPTX Rankings

LPTX Latest News

LPTX Latest SEC Filings

LPTX Stock Data

116.14M
49.89M
16.2%
22.06%
3.96%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE